OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.